SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Logo

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

A contract research organization providing comprehensive drug development services.

2395 | T

Overview

Corporate Details

ISIN(s):
JP3379950003
LEI:
Country:
Japan
Address:
鹿児島市宮之浦町2438番地

Description

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a contract research organization (CRO) providing comprehensive drug development services. Established in 1957 as Japan's first CRO, the company supports pharmaceutical clients throughout the development lifecycle, from preclinical safety studies to clinical trial management. SNBL offers a full suite of services, including safety assessments and clinical data management. A key area of innovation is its proprietary nasal drug delivery technology, SMART (Simple MucoAdhesive Release Technology). The company's mission is to contribute to medical advancement and alleviate patient suffering by supporting the creation of new pharmaceuticals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 03:55
確認書
Japanese 10.9 KB
2025-11-07 03:47
半期報告書-第53期(2025/04/01-2026/03/31)
Japanese 255.3 KB
2025-06-30 08:58
臨時報告書
Japanese 24.7 KB
2025-06-27 07:46
確認書
Japanese 8.2 KB
2025-06-27 07:40
内部統制報告書-第52期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-27 07:32
有価証券報告書-第52期(2024/04/01-2025/03/31)
Japanese 3.0 MB
2024-11-06 04:17
確認書
Japanese 10.8 KB
2024-11-06 04:11
半期報告書-第52期(2024/04/01-2025/03/31)
Japanese 253.7 KB
2024-06-26 04:52
臨時報告書
Japanese 24.6 KB
2024-06-25 07:06
確認書
Japanese 8.2 KB
2024-06-25 06:57
内部統制報告書-第51期(2023/04/01-2024/03/31)
Japanese 22.5 KB
2024-06-25 06:38
有価証券報告書-第51期(2023/04/01-2024/03/31)
Japanese 3.2 MB
2024-02-02 03:40
確認書
Japanese 10.8 KB
2024-02-02 03:39
四半期報告書-第51期第3四半期(2023/10/01-2023/12/31)
Japanese 203.9 KB
2023-11-07 07:18
確認書
Japanese 10.8 KB

Automate Your Workflow. Get a real-time feed of all SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.